Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
ARDX | US
-2.29
-30.25%
Healthcare
Biotechnology
31/03/2024
02/07/2024
5.28
6.25
6.47
5.07
Ardelyx Inc. a biopharmaceutical company discovers develops and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH which is in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis or hyperphosphatemia; RDX013 a potassium secretagogue for the treatment of elevated serum potassium or hyperkalemia a problem among certain patients with kidney and/or heart disease; and RDX020 for adult patients with metabolic acidosis a serious electrolyte disorder. The company has agreements with Kyowa Kirin Fosun Pharmaceutical Industrial Development Co. Ltd. and Knight Therapeutics Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx Inc. and changed its name to Ardelyx Inc. in June 2008. Ardelyx Inc. was incorporated in 2007 and is headquartered in Waltham Massachusetts.
View LessLow Market Beta (-0.4 to 0.8)
Strong Revenue Growth (> 10%)
Negative Momentum (Declining Price)
Weakness based on declining price with high volume
Price Below SMA10D
High Short-term Volatility
High 6-Month Volatility (>65%)
High Current Volume and Negative 1-Day Return
Smallcap (300M - 2B USD)
High Short percentage (> 15%)
Rich in Valuation (Price to Book > 8)
Weak Operating Margin (< 10%)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
184.5%1 month
127.8%3 months
101.0%6 months
96.0%-
-
9.85
0.70
0.31
-27.36
12.17
-0.08
-60.45M
1.24B
1.24B
-
-53.62
-
304.80
-47.64
8.91
15.13
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
2.99
Range1M
2.99
Range3M
4.26
Rel. volume
4.36
Price X volume
119.53M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Belite Bio Inc | BLTE | Biotechnology | 45.5 | 1.36B | -0.70% | n/a | 0.00% |
BioCryst Pharmaceuticals Inc | BCRX | Biotechnology | 6.55 | 1.35B | -1.80% | n/a | -173.65% |
Avadel Pharmaceuticals plc | AVDL | Biotechnology | 13.89 | 1.34B | -1.63% | n/a | 46.87% |
Arcus Biosciences Inc | RCUS | Biotechnology | 14.65 | 1.33B | -4.25% | n/a | 1.56% |
ANI Pharmaceuticals Inc | ANIP | Biotechnology | 62.64 | 1.31B | -1.26% | 39.55 | 68.66% |
Kiniksa Pharmaceuticals Ltd | KNSA | Biotechnology | 18.45 | 1.31B | 2.50% | 143.62 | 2.81% |
Verona Pharma plc | VRNA | Biotechnology | 15.46 | 1.25B | -0.32% | n/a | 22.79% |
immatics biotechnologies GmbH | IMTX | Biotechnology | 12.02 | 1.24B | 0.17% | n/a | 8.13% |
Longboard Pharmaceuticals Inc. Common Stock | LBPH | Biotechnology | 30.74 | 1.20B | -0.58% | n/a | 1.27% |
Sana Biotechnology Inc. Common Stock | SANA | Biotechnology | 5.35 | 1.19B | -2.19% | n/a | 28.28% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
REV Group Inc | REVG | Recreational Vehicles | 24.98 | 1.30B | 1.46% | 5.86 | 66.74% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 13.13 | 1.28B | 2.58% | n/a | 20.15% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.25 | 1.12B | 5.04% | n/a | -628.58% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 17.92 | 807.69M | 1.99% | n/a | 4070.84% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 33.09 | 676.35M | -2.01% | n/a | 4.21% |
Ennis Inc | EBF | Building Products & Equipment | 21.9 | 569.05M | 0.23% | 13.68 | 1.15% |
ACCO Brands Corporation | ACCO | Building Products & Equipment | 4.63 | 442.81M | 0.87% | n/a | 138.85% |
ONEWATER MARINE INC. | ONEW | Recreational Vehicles | 26.72 | 428.14M | 1.52% | n/a | 322.60% |
Lincoln Educational Services Corporation | LINC | Building Products & Equipment | 11.98 | 376.70M | 2.04% | 14.12 | 86.68% |
Latham Group Inc. | SWIM | Building Products & Equipment | 2.9 | 335.16M | 0.35% | 75.75 | 80.81% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -27.36 | -2.43 | Cheaper |
Ent. to Revenue | 12.17 | 4,101.76 | Cheaper |
PE Ratio | - | 41.26 | - |
Price to Book | 9.85 | 22.34 | Cheaper |
Dividend Yield | - | 2.39 | - |
Std. Deviation (3M) | 101.04 | 76.52 | Riskier |
Debt to Equity | 0.70 | 0.51 | Expensive |
Debt to Assets | 0.31 | 0.24 | Expensive |
Market Cap | 1.24B | 3.77B | Emerging |